Vivacitas Oncology

Next generation oncology therapy to treat solid tumors


(

Private Fundraise

This company may be interested in raising funds from accredited investors. You must Request Access to see more information about this company.

Request Access 9

BRINGING VISION TO LIFE, TOGETHER
Vivacitas Oncology: Overview

We are a clinical stage biopharmaceutical company developing new chemotherapy treatment.

Our lead development candidate (AR-67) is a novel lipophilic compound to target improved efficacy and tolerability through a novel proprietary synthesis method.

AR-67 has the potential to treat patients with recurrent and refractory solid tumors of the colon, rectum, lung, ovary, pancreas, brain, others.

BRINGING VISION TO LIFE, TOGETHER
A Need for Better
Cancer Treatment

Cancer patients who experience recurrence of disease must navigate a challenging prognosis and limited new treatment options.

While the current standard of care for tough to treat cancers can improve symptoms and manage disease progression, it also can have serious adverse effects.

There remains a substantial unmet need for new therapies that demonstrate improved efficacy, safety, toxicity and tolerability.

BRINGING VISION TO LIFE, TOGETHER
Next-Generation Solution 

Vivacitas’ development efforts focused on next-generation camptothecins:

  • Camptothecins inhibit the Topoisomerase-1 enzyme which impacts DNA replication and RNA transcription, thereby blocking the ability of tumor cells to multiply
  • Camptothecins have demonstrated efficacy in multiple tumor types and are FDA approved for use in colorectal, pancreatic, ovarian and small cell lung cancer
  • Currently approved camptothecins are naturally sourced from the bark and stem of the Camptotheca tree
  • Vivacitas’ AR-67 is synthetic, with potential advantages in purity, potency, efficacy, tolerability, safety, consistency of supply, and lower cost of goods

BRINGING VISION TO LIFE, TOGETHER
Key Features & Benefits

BRINGING VISION TO LIFE, TOGETHER
Company Milestones 

  • Preclinical and Phase I studies complete
  • Phase II data
  • Orphan Drug Designation (U.S. FDA)
  • Publications (see next section)
  • CMC demonstration batch qualified, GLP/GMP approach defined
  • Phase II clinical study plans/cost/timing defined:
    1) Umbrella Trial (colorectal, gastric, lung)
     
    2) Glioblastoma (brain cancer)


  • US Patent 9,447,126 B2 issued in 2015 (systems and methods for camptothecin analog synthesis); Expires 2035
  • Method of cancer treatment patent to reduce adverse events,  filed 


  • Significant industry experience in developing, registering, and monetizing biopharmaceutical assets
  • External advisors to guide scientific, clinical, medical execution
  • About Us – Vivacitas Oncology Inc (www.vivaoncology.com)

BRINGING VISION TO LIFE, TOGETHER
Vivacitas Publications 

We have 6 clinical study publications/references:

Phase I study publication: Arnold SM, et al. Clin Cancer Res. 2010;6:673-680

Preclinical, clinical development: Tsakalozou E. 2013. University of Kentucky. PhD thesis

Dosing models in NSCLC xenografts and humans: Tsakalozou E, et al. Cancer Chemother Pharmacol. 2014;74:45-54

Phase II study publication (abstract): Kumthekar P, et al. SNO 2019. Poster ACTR-40, published in Neuro-Oncology (https://academic.oup.com/neuro-oncology)

Population PK in cancer patients with solid tumors: Tang F, et al. Invest New Drugs 2019; (https://doi.org/10.1007/s10637-019-00744-0)

Phase II Imaging re-analysis using AI-assisted technology (abstract): Bisdas et al, 2021. SNO Poster CTNI-45, published in Neuro-Oncology

BRINGING VISION TO LIFE, TOGETHER
Our Founding Story 

Vivacitas Oncology was co-founded in 2015 by the late Dr. Joseph Rubinfeld (co-founder of Amgen) and Infusion 51a, LP to transform select chemotherapies with potency, toxicity, stability and/or pharmacokinetics challenges and unlock their efficacy and tolerability potential.

The Company is advancing next generation Camptothecins with its lead patented synthetic drug AR-67 in tough-to-treat solid tumor cancers.

BRINGING VISION TO LIFE, TOGETHER
Vivacitas Oncology: Overview

Mark Suseck, CEO & Director | Mr. Suseck is a global business leader with experience in sourcing, developing and launching products in biotech and specialty MedTech markets. 

Scott VanderMeer, MBA, Co-founder, CFO & Director | Mr. VanderMeer is a C-level business leader in the healthcare sector, venture capital and private equity. 

Tina Runk, MBA, Co-founder, EVP Clinical Operations & Director |  Ms. Runk has over 35 years of experience in research, preclinical and clinical development and operations.

Elise Brownell, PhD, EVP Portfolio Management | Dr. Brownell brings biopharmaceutical experience where she held key roles in discovery, development, opportunity assessment, and executive leadership. 

BRINGING VISION TO LIFE, TOGETHER
Meet Our Advisors 

The Business Plan area is locked. You must Request Access to this company to see more information including the Business Plan.


Request Access

N

No updates yet.




%

No backers yet.




Quick Signup TBD

You must have an account to do this!


the startups.com platform

Copyright © 2019 Startups.com. All rights reserved.

Fundable is a software as a service crowdfunding platform. Fundable is not a registered broker-dealer and does not offer investment advice or advise on the raising of capital through securities offerings. Fundable does not recommend or otherwise suggest that any investor make an investment in a particular company, or that any company offer securities to a particular investor. Fundable takes no part in the negotiation or execution of transactions for the purchase or sale of securities, and at no time has possession of funds or securities. No securities transactions are executed or negotiated on or through the Fundable platform. Fundable receives no compensation in connection with the purchase or sale of securities.